Clinical Trial Goal
To find out if surovatamig is safe and works well to treat DLBCL or follicular lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 to 80 years old
- Have DLBCL or follicular lymphoma that has relapsed or is refractory
- Have cancer cells with marker CD19 (CD19+)
- Do not have any of the following:
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL)
- Richter's transformation
- Do not have lymphoma in your brain or spinal cord
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not had an autologous (your own cells) BMT in the last 3 months
- Have not had CAR T-cell therapy in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Surovatamig is a bispecific T-cell engager (BiTE) that targets CD3 and CD19 on certain cells.
You’ll get:
You’ll get:
- Surovatamig – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to about 1 year. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has not yet approved surovatamig.
Contacts
AstraZeneca Clinical Study Information Center, 1-877-240-9479, information.center@astrazeneca.com
Locations
Sponsors
lead: AstraZeneca
